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ABSTRACT
BACKGROUND: While techniques for measuring IGF-1 have evolved over the decades, immunoassays 
are still the primary tool used in routine laboratories. ELISA, IRMA and Chemiluminescence IGF-1 kits 
are today on the market and their calibrators, specificity, sensitivity, cross-reactivity and prices differ sub-
stantially. Comparability studies are therefore valuable, especially if IGF-1 results obtained by one method 
should be interpreted retrospectively after transfer of patients from the pediatric to the adult endocrinolo-
gists.
AIM: To determine which of the used ELISA assays is closest to the IRMA IGF-1 assay and responds best to 
the Consensus Statement IGF-1 requirements from 2011.
MATERIAL AND METHODS: 24 patients aged 37.9±14.4 years, median 35; 12 females (42.25±16.6, me-
dian 38.5); 12 males (33.58±10.9, median 34.5) years.
The IGF-1 serum levels were measured by three different assays: Immunoradiometric (IRMA), IGFBP-
blocked Immunoenzymetric (ELISA1) and Immunoenzymetric with acid-ethanol extraction (ELISA2). The 
results were interpreted according to the kit referent values adjusted for age and gender. 
RESULTS: A very high positive correlation between the three assays (r=0.986 to 0.990) (p<0.01) was found. 
A significant difference was established only regarding the mean IGF-1 values measured by IRMA vs. ELI-
SA2 (р<0.05). The lowest IGF-1 mean value were measured by IRMA.
CONCLUSIONS: Closest to the IRMA method were IGF1 levels measured by the indirect “sandwich” ELI-
SA1 (IGFBP blocked) assay. Due to the significant difference between IRMA and the direct ELISA2 method, 
diagnostic pitfalls and therapeutic misinterpretations are possible. Priority has to be given to IGF-1 assays 
which best correspond to the Consensus Statement requirements from 2011. In this study this is fulfilled for 
the ELISA1, IGF blocked immunoassay. Future developments lie in fully automated assay systems, adapted 
to pediatric endocrine laboratories.
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INTRODUCTION
Growth hormone (GH) and insulin-like growth 
factor 1 (IGF-1) measurements are widely used in 
evaluation of children with short stature from mul-
tiple causes (13, 20) as well as in management of dis-
orders that lead to nutritional insufficiency or catab-
olism. They are cornerstones in the diagnosis of dis-
orders of GH secretion and monitoring both GH (16, 
22, 23) and IGF-1 replacement therapy (1,12). IGF-1 is 
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also suggested as an important marker in malignant 
(17,19) and metabolic diseases (3,15).
The GH secretion has a pulsatile pattern, while 
serum concentrations of IGF-1 and IGFBP-3 are rel-
atively stable during the day and therefore reflect the 
general long-term status of GH secretion. 
IGF-1 is the most important peripheral media-
tor of GH actions (18). It is a 70-amino acid protein, 
produced locally in many organs and tissues, but pre-
dominantly in the liver upon stimulation by GH. Cir-
culating IGF-1 is bound with high affinity to specific 
binding proteins (BPs), of which IGFBP-3 is the most 
abundant, and to an acid-labile subunit (ALS), form-
ing a ternary complex, retained within intravascular 
space and acting as a circulating reservoir of IGF-1 
(4). A variety of factors like gender, age, nutritional 
status, some pathological conditions, influence IGF-
1. The age-related pattern of IGF-1 secretion consists 
in a decline immediately after birth, followed by an 
increase until a pubertal peak. Later in life, values 
decrease continuously (8,14). While techniques for 
measuring IGF-1 have evolved over the decades (9), 
immunoassays are still the primary tool used in rou-
tine laboratories (7). The radioimmunoassays (RIA) 
were replaced later by the immunoradiometric assays 
(IRMA), enzyme immunoassays (EIA), fluoroim-
munoassays (FIA), automated chemiluminescence 
(6). Still considerable differences exist due to hetero-
geneity in assay characteristics between the currently 
available IGF-1 assays. Clinicians are therefore often 
challenged in accurate interpreting IGF-1 concentra-
tions. Laboratories have to face substantial problems 
with establishing new reference values if assay char-
acteristics change (6,14,16). Therefore, the practical 
utility of IGF-1 is undermined. 
Two of the clinical endocrine centers in Sofia – 
for adults and for children, perform IGF-1 determi-
nations by different assays: IRMA (Clinical Center 
for Endocrinology&Gerontology) and ELISA (Uni-
versity Pediatric Hospital, no license for work with 
radioactive materials). 
The aim of the current study is to test the com-
parability of the different non-radiometric assays 
based on ELISA methods and the IRMA for deter-
mination of serum IGF-1.
MATERIALS AND METHODS
Study design
Twenty four patients, aged from 19 to 69 years, 
average age 37.9, median 35 years were examined. 
Out of them 12 were female (average age 42.3, medi-
an 38.5) and 12 male (average age 33.6, median 34.5). 
IGF-1 in all samples was measured by three dif-
ferent assays (Table 1). Age, gender, pubertal stage, 
diagnosis and treatment of the patients were not tak-
en into consideration initially. The results were in-
terpreted according to the kit reference values. Sub-
sequently, the interpretations from the three assays 
were compared to each other, as well as with the di-
agnosis and the current treatment of the patients.
Healthy probands
36 healthy individuals, aged from 11 to 31, av-
erage age 22.9, median 22 years were included in the 
comparison between the two ELISA assays. Out of 
them 24 were females (average age 23.2, median 22 
years) and 12 males (average age 22.3, median 22 
years). The controls were stratified in the following-
age groups in order to interpret the measured IGF-1 
levels: 10-17 years (n=3; 2 female and 1 male); 18-30 
years (n=31; 20 female and 11 male) and 31-40 years 
(n=2; 2 female).
The serum of the patients and the healthy pro-
bands was collected and after one hour period at 
room temperature centrifugated at 5000 rpm. All 
samples were stored frozen at –20 Cº until the analy-
sis, according to the instructions of the producer. 
Analysis of serum IGF-1 levels
The serum levels of IGF-1 in the target group 
of patients (n=24) were determined by three differ-
ent assays:
 ❖ Immunoradiometric assay (IRMA IGF-1, Im-
munotech Beckman Coulter), calibrated against 
the World Health Organization (WHO) stan-
dard NIBSC 87/518. This is an indirect “sand-
wich” method: the patient’s samples are incu-
bated in tubes coated with monoclonal anti-
body against IGF-1 in the presence of second 
monoclonal antibody labeled with iodine 125. 
The intensity of radioactive reaction is propor-
tional to the concentration of IGF-I in the pa-
tient sera. 
 ❖ IGFBP-blocked enzyme immunoassay (IGF-
1–ELISA, Mediagnost, Germany), calibrat-
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ed against the WHO standard NIBSC 02/254. 
In order to dissociate IGF-1 from IGFBP’s, the 
samples are diluted in acidic buffer (pH<3.1). 
After the following neutralization (рН=7), an 
excess IGF-2 occupies the IGF-binding sites of 
the IGFBPs. The IGFBP’s are not removed, but 
their interference in the assay is neutralized. 
The method is an indirect “sandwich” ELISA. 
The IGF-1 in the samples binds to immobilized first 
antibody on the microtiter plate, and with a second 
specific streptavidin-peroxidase conjugated anti-
IGF-1 Antibody.
 ❖ Immunoenzymatic assay with acid-ethanol ex-
traction (IGF-1-ELISA, Diasource Immuno-
Assays S.A., Belgium), calibrated against the 
WHO standard NIBSC 02/254. The patient’s 
samples undergo a pre-treatment step – the ac-
id-ethanol procedure, proposed by William 
Daughaday in 1980. Due to the change in рН, 
IGF-1 and IGFBP’s are dissociated. The ethanol 
dilution precipitates IGFBP’s and therefore neu-
tralizes their interference with the assay.
The method is a direct concurrent ELISA. A 
fixed amount of IGF-1-labeled with horseradish per-
oxidase (HRP), compete with unlabeled IGF-1 pres-
ent in the samples for a limited number of binding 
sites on a specific antibody. After the incubation 
time, a chromogenic solution is added. The amount 
Тable 1. Characteristics of the assays, used for determining IGF-1 serum levels
IRMA ELISA Mediagnost ELISA Dia Source 
WHO international standard 
calibration 
WHO NIBSC 87/518 WHO NIBSC 02/254 WHO NIBSC 02/254 
Principles of IGF1/BP3 
dissociation 
Acid buffer dilution 
(pH <3.1); 
Blocked re-binding of 
BP3 with exes of IGFІІ 
Acid-ethanol extraction 








1 0 0 0 
2 30 2 10
3 100  5 25
4 300 15 62
5 600 30 226
6 1200 50 760
Range 2-1200 42-1050 
CV % Inter – 6.8% 
Intra – 6.3% 
Inter – 6.8% 
Intra – 6.7% 
Inter – 6.1% 





IGF II 0 ND 0,7 
Insulin 0 ND ND 
GH 0 ND ND 
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of substrate turnover is determined calorimetrically 
by measuring the absorbance, which is inversely pro-
portional to the IGF-1 concentration.The most im-
portant assay characteristics are summarized in ta-
ble 1.
Statistical analysis 
For comparison between the groups we used 
Student’s-Fisher t – test. The strength of the relation-
ship between the three assays was evaluated by cor-
relation and graphic analysis. To test the agreement 




To assess the difference between the mean IGF-
1 values of the three assays, a test of significance 
was performed. There was a significant difference 
(p<0.05) between the mean values of IGF-1 measured 
by IRMA and direct concurrent ELISA (Fig. 1, bar 
1 and 3). Between the measurements by IRMA and 
indirect “sandwich” ELISA no significant difference 
was found (p=0.3), as well as between the two ELISA 
methods (p=0.25) (Fig. 1). The lowest mean levels of 
IGF-1 were determined by IRMA. 
Fig. 1. Comparison of the mean serum IGF-1 values 
between the three assays: Analysis 1 –direct concurrent 
ELISA; Analysis 2 – Indirect “sandwich” ELISA; Analysis 
3 – IRMA
Fig. 2. Correlation between the three assays for determining serum levels of IGF-1; a) A very high positive correlation 
between indirect “sandwich” ELISA and direct concurrent ELISA; b) A very high positive correlation between indirect 
“sandwich” ELISA and IRMA; c) A very high positive correlation between direct concurrent ELISA and IRMA
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Correlation analysis 
The performed correlation analysis showed a 
very high positive correlation between the three as-
says r = 0.986 to 0.990 (p<0.01) (Fig. 2) and a strong 
linear relationship between them as well.
Test for agreement between the three assays
Bland-Altman analysis showed good agreement 
between indirect “sandwich” ELISA and IRMA (Fig. 
3b), with a relatively low bias of 7.3 ng/ml and accept-
able limits of agreement (±2SD range of the measure-
ment differences). Lesser agreement was found in the 
comparison of the two ELISA assays (Fig. 3a) with a 
higher bias of 11.2 ng/ml and a comparably large lim-
its of agreement. Poor agreement was found between 
direct concurrent ELISA and IRMA (Fig. 3c) with a 
bias of 18.5 ng/ml and large limits of agreement.
DISCUSSION 
Several IGF-1 studies including creation of ref-
erence values were undertaken in Bulgaria during 
the last decade. Methods, as well as patient’s groups 
were different (2-3, 22, 23-24). This study is aimed 
to provide some data which could help in choosing 
the most appropriate assay for diagnosing and con-
trolling treatment of growth hormone deficiency in 
children and adolescents. The lack of consistency of 
the different assays, even from one and the same pro-
ducer, combined with problems in the reagent’s sup-
ply, represent problems which should be solved in the 
light of the new Consensus Statement on the Stan-
dardization and Evaluation of Growth Hormone and 
IGF assays (12). The need for harmonization of the 
IGF-1 assays is challenging also the Bulgarian endo-
crinologists - the pediatricians as well the internists.
In the present study we could show substantial 
differences between the mean IGF-1 concentrations 
in one and the same patients and healthy probands 
by two different ELISA assays and IRMA. The high-
est IGF-1 levels were measured by direct ELISA (Im-
munoenzymatic assay with acid-ethanol extraction), 
followed by the other ELISA assay (IGFBP blocked) 
and the IRMA. The IGF-1 difference was significant 
only between the ELISA with acid-ethanol extrac-
tion and the IRMA assay (Fig. 1). These findings are 
not unexpected, and the differences of results among 
assays are most probably due to the methodology, 
different calibrators and study cohorts.
In general, immunoassays ‘measure’ the inter-
action between the analyte and specific antibodies 
that bind to a distinct 3-dimensional structure on 
the surface of the analyte, or ‘epitope’. The binding 
of the analyte is translated into a measurable signal 
in various ways, depending on the assay design. In 
all immunoassays, the signal generated from a giv-
en patient’s sample is compared with the signal gen-
erated by a known amount of the analyte in a series 
of standardized samples (standard curve). The mea-
surement principle used for quantification of ana-
lytes has two major limitations, the antibody specif-
ity and the standard preparation used. Depending on 
the antibody specifity, any modification of the acces-
sibility of an epitope recognized by the antibody will 
also modify the assay’s result. The presence or ab-
sence of IGFBP’s in a sample presents a major chal-
lenge, as high affinity BP’s can ‘cover’ epitopes recog-
nized by the antibodies used in an assay (7). In gener-
al, IGFBP’s interfere with IGF-1 detection to produce 
falsely low values (12). All IGF-1 assays involve some 
kind of extraction or at least acidification to dissoci-
ate the complexes formed by IGF-1, IGFBP’s and ALS. 
The methods differ significantly in their ability to re-
move IGFBP’s completely. The acid-ethanol extrac-
tion does not sufficiently eliminate potential interfer-
ence from smaller IGFBP’s (5,21). The disadvantages 
of the classic extraction procedures can be circum-
vented by blocking the IGFBP–binding sites through 
an excess of non-measured IGF-2 in the IGF-1 assay 
(9-10). Because highly specific antibodies to IGF-1 
do not cross-react with IGF-2, an excess of IGF-2 is 
added during the acid-ethanol precipitation step, be-
fore IGF-1 measurement. The high concentration of 
IGF-2 blocks the IGF-1 binding sites of the remain-
ing BP’s, thereby allowing an unbiased measurement 
of IGF-1. Two steps take place before the IGF-1 mea-
surement: separation of IGF-1 and IGFBP’s and then 
removal of IGFBP’s (“functional separation of IGF’s 
from IGFBP’s”) to prevent re-association. This third 
generation IGF assays offers a number of advantag-
es over assays using extraction procedures, because 
they are: a) more simple, b) more precise, c) markedly 
more sensitive, d) completely suitable for fully auto-
mated systems. Therefore, the different IGFBP elim-
ination methods in the three assays could be a very 
important factor explaining the differences in the 
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mean serum IGF-1 levels in our patients and healthy 
probands.
Another issue affecting the comparability of 
IGF-1 assay results is assay standardization. The in-
ternational reference preparation 87/518 is impure, 
containing approximately 40% IGF-1 (25) and is used 
in the IRMA assay. The IS 02/254 WHO reference 
standard has recently became available. It is a >97% 
pure recombinant standard and therefore recom-
mended officially (12) in order to minimize the inter-
assay differences that arise from use of different stan-
dards. The mean IGF-1 values obtained by the ELISA 
assays are higher and closer to each other than the re-
sults obtained by IRMA, also due to the usage of the 
recommended 02/254 WHO reference standard. 
We included in the study patients with growth 
hormone deficiency (GHD) before and during treat-
ment with recombinant human (rh) rhGH and 
healthy subjects as well. The individuals were one 
and the same in order to exclude variations in IGF-
1 levels due to differences in the investigated cohort.
Direct comparisons of IGF-1 levels are difficult 
because of methodological and standards differenc-
es. From our data, there is a strong correlation be-
tween the three assays r=0.986 to r=0.990 (Fig. 2a, 
b, c). Therefore it is safe to conclude that the mea-
surements are related. This result is expected and in 
agreement with other studies (8). Nevertheless a high 
correlation does not mean that two methods agree, 
or prove that they are replaceable.
To understand how much one method (non-ra-
diometric ELISA assays) is likely to differ from the 
IRMA, an evaluation of the agreement between the 
assays is required. If the estimated difference is not 
enough to cause misinterpretation, they can replace 
one another. 
The Bland-Altman plot was used for estimation 
of the agreement between the assays. This plot was 
introduced in 1986 by Martin Bland and Douglas 
Altman. They propose an alternative way of compar-
ing different measurement methods by plotting not 
the actual values against each other, but the differ-
ences against the mean values (11). 
To understand how much the estimated agree-
ment would affect the clinical interpretation of the 
result, a calculation of the mean differences, or bias 
(d), and the standard deviation of the differences 
is needed. It is expected for most of the differences 
(95%) to lie between d+2SD and d – 2SD, if they are 
normally distributed. Those limits are referred as a 
Fig. 3a, 3b, 3c
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“limits of agreement”. If the limits are within d±2SD, 
they would not be clinically important and the assays 
could be used interchangeably. 
We found that the indirect “sandwich” ELISA1 
(IGFBP blocked) and IRMA are in good agreement, 
with relatively low bias of 7.3 ng/ml and acceptable 
limits of agreement (Fig. 3b). This result leads to the 
conclusion that the probability of misinterpretation 
is relatively low if IGF-1 comparison between the two 
centers is needed. 
Lesser agreement was found in the comparison 
of the two ELISA assays (Fig. 3a) with a higher bias 
of 11.2 ng/ml and a comparably large limits of agree-
ment. Usage of direct concurrent ELISA2 instead of 
indirect “sandwich” ELISA1 could result in higher 
levels of serum IGF-1 followed by false interpretation 
of the analysis. This may lead to missing the diagno-
sis GHD or to incorrect dosing of rhGH.  
Poor agreement was found between direct con-
current ELISA2 and IRMA (Fig. 3c) with a bias of 
18.5 ng/ml and large limits of agreement. These two 
methods do not agree with each other. The use of di-
rect concurrent ELISA can cause under- or over-di-
agnosis and under- or overtreatment. 
CONCLUSIONS
Closest to the IRMA method were IGF-1 lev-
els measured by the indirect “sandwich” ELISA1 
(IGFBP blocked) assay. Due to the significant dif-
ference between IRMA and the direct ELISA meth-
od, diagnostic pitfalls and therapeutic misinterpreta-
tions are possible, especially in borderline cases. Pri-
ority has to be given to IGF-1 assays which best cor-
respond to the Consensus Statement requirements 
from 2011. In this study this is fulfilled for the ELISA 
IGF blocked immunoassay. Future developments lie 
in fully automated assay systems, adapted especially 
for pediatric endocrine laboratories.
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